CHMP delivers negative opinion on duloxetine in fibromyalgia
This article was originally published in Scrip
The EU's CHMPhas adopted a negative opinion on extending the indications forLilly/Boehringer Ingelheim's antidepressant duloxetine (Cymbalta/Xeristar) 30mg and 60mg tablets to include the treatment of fibromyalgia. In contrast the US FDA approved the additional indication in June (Scrip Online, June 17th, 2008).
You may also be interested in...
Emerging Company Profile: Austria’s OncoOne could have an anticancer biologic which targets oxidized macrophage migration inhibitor factor ready for the clinic in around two years.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Mundipharma has announced the European Commission’s extension of the indications for Invokana to include renal outcomes data from the Phase III CREDENCE study.